Patents by Inventor Carlos L. Arteaga

Carlos L. Arteaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunological compositions as cancer therapeutics
    Patent number: 9745377
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: August 29, 2017
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Paula R. Pohlmann, Raymond L. Mernaugh, Carlos L. Arteaga
  • IMMUNOLOGICAL COMPOSITIONS AS CANCER THERAPEUTICS
    Publication number: 20160053010
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Application
    Filed: May 5, 2015
    Publication date: February 25, 2016
    Inventors: Paula R. POHLMANN, Raymond L. MERNAUGH, Carlos L. ARTEAGA
  • Combinations of kinase inhibitors for the treatment of cancer
    Patent number: 9011863
    Abstract: The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: April 21, 2015
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent
  • Combinations of Kinase Inhibitors for the Treatment of Cancer
    Publication number: 20140271665
    Abstract: The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.
    Type: Application
    Filed: July 8, 2011
    Publication date: September 18, 2014
    Applicants: Exelixis, Inc., Sanofi, Vanderbilt University
    Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent
  • Immunological compositions as cancer therapeutics
    Patent number: 8486413
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: July 16, 2013
    Assignee: Vanderbilt University
    Inventors: Paula R. Pohlmann, Raymond L. Mernaugh, Carlos L. Arteaga
  • IMMUNOLOGICAL COMPOSITIONS AS CANCER THERAPEUTICS
    Publication number: 20120201820
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Application
    Filed: December 8, 2011
    Publication date: August 9, 2012
    Inventors: Paula R. Pohlmann, Raymond L. Mernaugh, Carlos L. Arteaga